C. Michael Gibson/LinkedIn; Ulf Landmesser/FRIEDE SPRINGER
Cardiovascular
Prevention
Center Charité
Nov 9, 2025, 12:33
C Michael Gibson and Ulf Landmesser Discuss Insights from CLOSURE-AF trial
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Ulf Landmesser and I discuss the CLOSURE-AF trial:
In AF patients with high risk of stroke and bleeding, is LAA occlusion as effective and safe compared to optimal medical therapy?
View it here.”
Stay updated with Hemostasis Today.
-
Nov 9, 2025, 12:37Deise Catamo Vaz Wins Merit Award for Raising Stroke Awareness in Mozambique
-
Nov 9, 2025, 12:34Abena Ntim Asamoah on The Race to End Preventable Maternal Deaths in Africa
-
Nov 9, 2025, 12:34Christian Schulze Shares the CLOSURE AF Insights on Left Atrial Appendage in AFib
-
Nov 9, 2025, 12:32Shakira J Grant on How can AI Transform Outcomes for Patients Who Need It Most?
-
Nov 9, 2025, 12:32Amre Nouh and Ahmed Koriesh on The Future of Post-Stroke Care
-
Nov 9, 2025, 12:31Teagan Prouse and Colleagues on Alternate Functions of Physiological Anticoagulants
-
Nov 9, 2025, 12:30Hema Tallman Congratulates Richard Wilner on Receiving the Sustainability in Life Sciences Award
-
Nov 9, 2025, 12:29Sophie Hordijk on A New Cause of the Hereditary Bleeding Disorder of VWD Type 1
-
Nov 9, 2025, 12:28Oh Young Bang on Enhancement of Post-Stroke Neuroregeneration